The cyclin-dependent kinase (CDK) inhibitor p27 KIP1 exerts its growth suppressive effects by targeting the cyclin-CDK complexes. Reduced protein levels of p27 KIP1 have been reported in numerous human cancers and this has been attributed to increased degradation. However, few reports have addressed the significance of p27 KIP1 expression in chemical carcinogenesis of rodents. In a rat two-stage urinary bladder carcinogenesis model, with N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN) initiation followed by promotion with sodium L-ascorbate (Na-AsA), we evaluated the expression of p27 KIP1 protein using immunohistochemistry during various stages of urinary bladder carcinogenesis. In addition, we evaluated the mRNA expression profiles for p27 KIP1 , p21 WAF1/Cip1 and p53 in tumors. Fisher 344 rats were initiated with 0.05% BBN in the drinking water for 4 weeks and then administered 5% Na-AsA in the diet. Immunohistochemical examination revealed p27 KIP1 protein to be constitutively expressed in normal urothelium, simple hyperplasia and in most papillary and nodular (PN) hyperplasias and small papillomas, but diminished or absent in large papillomas and in transitional cell carcinomas. An inverse correlation between expression of p27 KIP1 and cell proliferation was generally observed. Quantitation of mRNA by multiplex reverse transcription-PCR showed a significant downregulaton of p27 KIP1 , p21 WAF1/Cip1 and p53 mRNA in tumors. More than 50% reduction in p27 KIP1 mRNA expression was observed in 42 and 47% of tumors at weeks 18 and 24, respectively; similar reduction in p21 WAF1/Cip1 mRNA expression was observed in 58 and 73% of tumors at weeks 18 and 24, and in p53 mRNA expression in 50 and 73% of tumors at weeks 18 and 24, respectively. None of the 25 tumors we examined by PCR-single-strand conformational polymorphism analysis had p53 mutations. These data imply that abnormal down-regulation of p27 KIP1 , p21 WAF1/Cip1
Introduction
Knowledge of cell cycle regulation has advanced rapidly over the past several years due to the discovery of an increasing number of cell cycle regulatory proteins, namely the cyclins, cyclin-dependent kinases (CDKs) and CDK inhibitors. Recently, a number of cell cycle related elements was found to be either inactivated or overexpressed in transformed cell lines or tumors. Although the regulation of cell cycle regulatory proteins has thus been extensively studied in vitro using tumor cell lines, there have been relatively few studies of this kind in vivo using animal tumor models. Recently, cell cycle regulatory events in tumors have been analyzed in vivo using several animal models of carcinogenesis (1) (2) (3) , including neoplasia in the urinary bladder (4) . In contrast to genetic alterations found in human cancers, which are potentially due to a multitude of environmental carcinogens and genetic factors, those in tumors induced by chemical carcinogens in inbred animals are more likely to be attributable to the effects of the carcinogens administered. Usually only a single carcinogen is administered in simple protocols. Induction of neoplasms with carcinogens in rodents followed by analysis of cell cycle related elements in the preneoplastic lesions and tumors at various stages of their development should contribute to understanding the relationship between cell cycle deregulation and the development of malignancies in vivo.
Numerous urinary bladder carcinogenesis models has been developed using rats and mice, typically by administration of chemical carcinogens in the food or the drinking water (5) (6) (7) (8) . Animal models of urinary bladder carcinogenesis are useful for studies of tumor biology for the following reasons: firstly, progression from preneoplastic lesions to carcinomas can be readily observed, thus allowing comparison of genetic events in precursor lesions with those in tumors. Secondly, stagespecific molecular events in urinary bladder carcinogenesis can be analyzed readily in experimental systems using the multistage carcinogenesis protocol of initiation and promotion. Thus, multistage chemical carcinogenesis of rat urinary bladder provides an excellent model for the study of multistep progression from preneoplastic changes to carcinoma, and studies in this model have led to significant advances in our understanding of urinary bladder carcinogenesis. Chemical carcinogens are generally divided into two categories, genotoxic and nongenotoxic (including tumor promoters). Genotoxic carcinogens are capable of directly interacting with and disrupting the integrity of genomic DNA, and are believed to play a role in the carcinogenic process by causing mutations in protooncogenes or tumor suppressor genes (9) . In contrast, the mechanisms of action of non-genotoxic carcinogens are much less well understood. One of the most widely employed and well characterized experiment protocols for urinary bladder carcinogenesis in rats is the two-stage bladder carcinogenesis protocol, which consists of initiation with a genotoxic carcinogen such as N-butyl-N- (4-hydroxybutyl) (FANFT) for a period of 4-6 weeks, followed by promotion with a nongenotoxic carcinogen such as sodium L-ascorbate (Na-AsA) or sodium saccharin for the duration of the experiment (6, 7) . Currently, little is known about the mechanism of promotion by non-genotoxic carcinogens in rat urinary bladder carcinogenesis. A recent study indicated that cyclin D1 overexpression, and subsequently accelerated cell cycle entry, is involved in rat two-stage bladder carcinogenesis (4); consistent with the view that increased cell proliferation might account for the carcinogenicity of non-genotoxic chemicals (10, 11) . Since cancer cells typically undergo a series of genetic alterations during the course of promotion and progression, additional genetic events are likely to be associated with two-stage bladder carcinogenesis. We postulated that downregulation of CDK inhibitors, negative effectors of the cell cycle, is one possibility.
nitrosamine (BBN) or N-[4-(5-nitro-2-furyl)-2-thiazole]formamide
The CDK inhibitors can be grouped into two categories which differ in sequence homology and their targets of inhibition; the INK4 family containing ankyrin repeat motifs (p16 INK4a , p15 INK4b , p18 INK4c and p19 INK4d ) (12) (13) (14) (15) and the CIP/KIP family (p21 WAF1/Cip1 , p27 KIP1 and p57 KIP2 ) (16) (17) (18) (19) (20) . The INK4 family of CDK inhibitors are specific inhibitors of CDK4/6 complexes while p27 KIP1 and p21 WAF1/Cip1 are able to suppress cell cycle progression via inhibition of a diverse family of preactivated cyclin-CDK complexes (18, 19, (21) (22) (23) .
In the present study, we focused our attention on altered expression of p27 KIP1 (21, 24, 25) , a candidate tumor suppressor yet to be implicated in bladder neoplasia. Reduced expression of p27 KIP1 has been reported in a variety of human cancers and is associated with patient outcome (26) ; notably in breast carcinomas (27) (28) (29) , in colorectal carcinomas (30, 31) , in gastric carcinomas (32) , in small cell and non-small cell lung carcinomas (33, 34) , in pituitary tumors (35, 36) , in follicular carcinomas of the thyroid (37), in prostatic adenocarcinomas (38) (39) (40) , in carcinomas of the oral cavity (41) and in esophageal adenocarcinomas (42) . However, mutations in the p27 KIP1 gene are extremely uncommon in human tumors (36, (43) (44) (45) (46) . We have evaluated the expression of p27 KIP1 at the protein level using immunohistochemistry for urinary bladder lesions during various stages of their development in a rat two-stage urinary bladder carcinogenesis model, namely initiation with BBN followed by promotion with Na-AsA (7). In addition, mRNA expression profiles for p27 KIP1 , p21 WAF1/Cip1 and p53 were examined along with the mutational status of the p53 gene. Expression patterns of p27 KIP1 in urinary bladder lesions were also compared with those of PCNA and cyclin D1. Finally, we discuss the possible implications of these changes in twostage carcinogenesis of the rat urinary bladder.
Materials and methods
Chemicals BBN and Na-AsA were purchased from Tokyo Kasei (Tokyo, Japan) and Wako (Osaka, Japan), respectively.
Animals
A total of 79 5-week-old, male F344/DuCrj rats (Charles River Japan, Shiga, Japan) were quarantined for 1 week before the start of the experiment. They were housed five per cage in an animal facility with a 12 h light-dark cycle at a temperature of 22 Ϯ 2°C and 44 Ϯ 5% relative humidity and were given 1698 free access to tap water and food (Oriental MF; Oriental Yeast Co., Tokyo, Japan). Bedding and cages were changed twice per week. The animals were observed daily, and body weights were measured weekly throughout the experiment.
Experimental design
Rats were divided into two groups, experimental and control. Those of the experimental group were administered 0.05% BBN in their drinking water for 4 weeks followed by 3 days of non-treatment and then 5% Na-AsA in powdered basal diet (Oriental MF) until killing. Rats of the control group were maintained on the basal diet without any treatment. The total period of observation was 24 weeks, and subgroups were killed at weeks 4, 8, 12, 18 and 24 in the experimental group and weeks 4 and 24 in the control group. At each time of killing, 10 urinary bladders from the experimental group and five urinary bladders from the control group were fixed in 10% neutral buffered formalin. The urinary bladders were distended with the fixative and then stored overnight at 4°C; after fixation, they were divided sagitally, and the number of tumors in each bladder was recorded. For histological analysis, the urinary bladders were cut into 12 strips, routinely processed for embedding in paraffin, sectioned, and stained with H&E. For molecular assessment, four animals at week 18 and five animals at week 24 were killed, and the three largest tumors from each urinary bladder were removed and stored at -80°C until they were analyzed. After tumor removal, the remaining bladder tissues were stretched and fixed in formalin for histological examination. A total of 10 age-matched control rats were killed and their urinary bladder mucosae were removed for molecular assessment.
Pathological diagnosis
Serial sections from each block were stained with H&E for histopathological assessment. Lesions of the urinary bladder were classified into simple hyperplasia, PN hyperplasia, papilloma, TCC, squamous cell papilloma and SCC, as described previously (47) .
Immunohistochemistry
Serial sections of 3 µm thickness were made and spread on poly-L-lysinecoated slides (48) . Paraffin sections were immersed in three changes of xylene and hydrated using a graded series of ethanols. Antigen retrieval was performed routinely by microwave heating. Sections were immersed in distilled water or buffer inside a plastic container and were repeatedly heated to boiling temperature and then allowed to cool to room temperature gradually for eight to 10 times (4,49,50); for p27 KIP1 immunohistochemistry, distilled water was used, and for PCNA, cyclin D1 or p53 immunohistochemistry, an antigen retrieval fluid (AR-10; BioGenex, San Ramon, CA) was employed. Sections were blocked with serum at 37°C for 30 min and then incubated with either mouse monoclonal anti-p27 KIP1 antibody (IgG1; Transduction Laboratories, Lexington, KY) at 1:50 dilution, mouse monoclonal anti-PCNA antibody (PC-10, IgG2a; Dako, Tokyo, Japan) at 1:750 dilution, rabbit polyclonal anticyclin D1 antibody (IgG; UBI, Lake Placid, NY) at 1:200 dilution, or rabbit polyclonal antihuman p53 antibody (CM1; MedacDiagnostica, Germany) at 1:200 dilution, overnight at 4°C. Staining was achieved with a Dako LSAB2 kit/AP (Dako A/S, Glostrup, Denmark) and developed with either 3-amino-9-ethylcarbazole (Zymed Laboratories, San Francisco, CA) or 3,3Ј-diaminobenzidine tetrahydrochloride (Zymed). Sections were counterstained for 5 s with Meyer's hematoxylin and mounted in non-aqueous mounting media (DIATEX; AB Wilh, Becker, Sweden) for microscopy. A negative control staining was included with each staining procedure by omitting the primary antibody. Sections of human TCCs with intense staining for either p27 KIP1 or PCNA were included with each staining procedure and served as positive controls (49, 50) . The epitope for the anti-p27 KIP1 mouse monoclonal antibody corresponds to the C-terminus of mouse p27 KIP1 . The antibody detects a specific band of 27 kDa on western blot analysis of HeLa Cell extracts, as indicated by its information data sheet. The antibody also reacts with p27 KIP1 of human, dog, rat and chicken origin by immunohistochemistry and is immunoreactive in formalin-fixed, paraffin-embedded tissues (28, 51) . The epitope for anti-PCNA mouse monoclonal antibody is the mouse PCNA antigen and the antibody has species cross-reactivity to human and rat. The anti-cyclin D1 antibody recognizes the 11 C-terminal amino acids (residues 285-295) of human cyclin D1 and has species cross-reactivity to mouse and rat. The anti-p53 antibody (CM1) recognizes both wild and mutant forms of p53 on formalin-fixed, paraffin-embedded specimens. For double staining of p27 KIP1 and PCNA or p27 KIP1 and cyclin D1, sections were first probed with anti-p27 KIP1 antibody overnight and developed with the alkaline phosphatase method (BCIP/NBP chromogen) to produce a dark purple to black color. After incubation with double staining enhancer (Zymed Laboratories) for 30 min, sections were reprobed with the anti-PCNA or anti-cyclin D1 antibody overnight and developed with the peroxidase method to produce a red color (AEC chromogen). Sections were briefly counterstained with Meyer's p27 KIP1 in urinary bladder carcinogenesis KIP1 ; the intensity of staining was moderate (ϫ100). (H) Large papilloma with weak staining for p27 KIP1 (ϫ100). (I) TCC with abundant stroma; note the intense staining of p27 KIP1 present in the fibroblasts but not in the epithelial elements (ϫ200). (J) TCC with negligible p27 KIP1 (brown) nuclear staining (ϫ100). (K) Serial section to J stained for PCNA (red) showed intense nuclear staining for the majority of tumor nuclei (ϫ100). (L) TCC with little stroma showing very weak staining of p27 KIP1 in the epithelial elements (ϫ200).
hematoxylin and then mounted in AQUATEX aqueous mounting media (Merck KGaA, Darmstadt, Germany) for microscopy. Quantitation of p27 KIP1 immunohistochemistry Cells were considered positive for p27 KIP1 when definite nuclear staining could be identified. Intense staining of p27 KIP1 was consistently observed in simple hyperplasia and in fibroblasts, which served as internal controls for the quality of staining ( Figure 1B and I). The intensity of p27 KIP1 staining in PN hyperplasias, papillomas and TCCs was compared with regions of simple hyperplasia with strong intensity of staining within the same specimen, and was judged on a semi-quantitative scale of negative staining, weak staining, moderate staining or strong staining by the consensus of two pathologists (C.C.R.Lee and T.Ichihara). All visible PN hyperplasias, papillomas and TCCs, at different stages of development, were evaluated ( Figure 1 ). Lesions with a markedly heterogeneous staining pattern for p27 KIP1 were not classified. Few squamous cell carcinomas (SCCs) and squamous cell papillomas were encountered and they are not analyzed in the present study.
Extraction of DNA and RNA Bladder tumor specimens for RNA extraction were snap frozen in liquid nitrogen and stored at -80°C until they were analyzed. Tumors Ͻ5 mm were homogenized whole, and larger lesions were divided into smaller pieces. Total 5Ј-AGG AGA GCT TGG ATG TCA G-3Ј  sense  53  19  207  50  5:1  5Ј-TTT CTT CTG TTC TGT TGG CC-3Ј  antisense  45  20  p21 WAF1/Cip1 5Ј-ACG TGG CCT TGT CGC TGT CTT-3Ј  sense  57  21  213  55  2.5:1  5Ј-TAA GGC AGA AGA TGG GGA AGA G-3Ј antisense  50  22  p53  5Ј-CCT CAA TAA GCT GTT CTG CC-3Ј  sense  50  20  250  50  5:1  5Ј-AAA AGT CTG CCT GTC GTC CA-3Ј  antisense  50  20  GAPDH  5Ј-CTC TGG AAA GCT GTG GCG TGA T-3Ј  sense  55  22  560  50 or 55  -5Ј-CTG GGA TGG AAT TGT GAG GGG G-3Ј  antisense  55  22 RNA was isolated from tumors using ISOGEN (Nippon Gene, Toyama, Japan) (52,53), a reagent for simultaneous isolation of RNA and DNA from tissue samples. Tumor tissues were placed in ISOGEN and lysed by repeated passage through a syringe fitted with a 23 gauge needle. After removal of the RNA fraction, DNA was ethanol precipitated and then extracted with SepaGene (Sanko Junyaku, Tokyo, Japan). DNA concentrations were determined with a spectrophotometer and adjusted to a final concentration of 50 ng/µl with InstaGene Purification Matrix (Bio-Rad, Hercules, CA). RNA was stored at -80°C and DNA at -30°C until they were analyzed. For the extraction of total RNA from normal rat urinary bladder epithelium, urinary bladders were removed and inverted over the blunt end of a sterilized toothpick and immediately immersed in pre-chilled Isogen in an Eppendorf tube placed on ice. The exposed mucosal lining was removed by repeated brushing against the inner wall of the Eppendorf tube. The urothelial cells were resuspended in Isogen and lysed by repeated aspiration through a syringe fitted with a 23 gauge needle. Control DNA for PCR-single cell conformation polymorphism (SSCP) analyses was extracted from the livers and brains of control animals with SepaGene.
Multiplex RT-PCR
Urinary bladder tumors obtained from the 18th and 24th week killings were selected for RNA extraction, and the mRNA levels of p27 KIP1 , p21 WAF1/Cip1 and p53 were examined by multiplex RT-PCR. Total RNA extracted from the bladder mucosa of 10 age-matched control rats was similarly analyzed. The RNA concentrations were determined with a spectrophotometer (Ultraspec 3000, UV/Visible Spectrophotometer; Pharmacia Biotech, Tokyo, Japan). For cDNA synthesis, up to 5 µg of total RNA were mixed with 1 µl of oligodeoxythymidylate 15 primer (Biotech International, Bentley, Australia) and 1 µl of RNase inhibitor (Boehringer Mannheim, Mannheim, Germany) in a total volume of 9 µl. The samples were heated to 70°C for 10 min and then placed immediately on ice for 10 min. To each sample, 4 µl of 5ϫ reverse transcriptase buffer, 2 µl of 0.l M DTT, 4 µl of deoxynucleotide triphosphate mix (containing 2 mM of each dNTP; GeneAmp dNTP MIX; Perkin Elmer Applied Biosystems, Branchburg, NJ) and 1 µl of Superscript II reverse transcriptase (Gibco BRL, Rockville, MD) were added. Reverse transcriptions were carried out at 42°C for 50 min, followed by heating at 70°C for 15 min. Template RNA was degraded by the addition of RNase (Boehringer Mannheim), which had been isolated from bovine pancrease and purified by column chromatography, and incubation at 37°C for 3 h. Samples were heated to 75°C for 15 min and the concentration of cDNA was adjusted to 100 ng/µl. Primer pairs for multiplex RT-PCR were designed with software (Genetyx-Mac v.7.3; Software Development Co.) using the cDNA sequences obtained from GenBank (accession numbers: p27 KIP1 , D86924; p21 WAF1/Cip1 , U24174; p53, X13058; GAPDH, X02231 and X00972). Multiplex PCR was carried out in a reaction volume of 5 µl containing 50 nM [α-32 P]dCTP (sp. act. Ͼ3000 Ci/mmol), with two sets of primers (25 cycles of 95°C for 60 s, 50°C or 55°C for 60 s and 72°C for 60 s). The conditions for RT-PCR were optimized by varying the annealing temperatures, the ratios of target primer pairs to GAPDH primer pairs, and the number of PCR cycles. The nucleotide sequences of the primers and relevant properties are listed in Table I . PCR products were electrophoresed through 3% SeaKem GTG agarose gels (FMC BioProducts, Rockland, ME), transferred to Hybond Nϩ nylon membranes (Amersham, Little Chalfont, UK) and then exposed to X-ray film. The images were digitized, recorded onto a diskette, and quantitated with image analysis software (NIH image, Bethesda, MD) on a personal computer (Power Macintosh 7500; Apple Computer, Cupertino, CA). Peak intensity of the PCR product derived from the target gene was divided over that for GAPDH, the internal control for multiplex PCR. The results obtained from five separate PCR reactions were averaged to represent the relative gene expression for any particular sample. The average relative gene expressions of control rats (normal bladder mucosa) were assigned an arbitrary value of one, with which the tumor samples were compared.
PCR-SSCP analysis
Exons 5, 6 and 7, and 8 and 9 of p53 were analyzed by the PCR-SSCP method (4, 54, 55) . Fifty nanograms of genomic DNA were amplified in a reaction volume of 5 µl containing 50 nM [α-32 P]dCTP (Ͼ3000 Ci/mmol; NEN/Dupont, Boston, MA). The PCR conditions for exon 5 were 38 cycles of 95°C for 60 s, 58°C for 60 s and 72°C for 60 s, and for exons 6-8 and 8-9 were 38 cycles of 95°C for 60 s, 56°C for 60 s and 72°C for 60 s. PCR products were mixed with 20 µl of stop solution containing 95% formamide, 20 mM EDTA, 0.05% bromophenol blue and 0.05% xylene cyanol, denatured for 5 min at 90°C and loaded (3 µl/lane) to mutation detection enhancement gels (modified acrylamide gels; AT Biochem, Malvern, PA), a polyacrylamidelike matrix that has a high sensitivity to DNA conformational differences, and electrophoresed for 16 h at 6 W. Gels were dried and exposed to X-ray film at -80°C with Kodak X-OMAT AR film (Kodak, Rochester, NY) and an intensifying screen. The sequences of primers for the PCR-SSCP analysis were as follows: p53 exon 5, 5Ј-GATTCTTTCTCCTCTCCTAC-3Ј (sense) and 5Ј-ACAGGCAGTGCCAGTGCTCA-3Ј (antisense); p53 exons 6 and 7, 5Ј-CCTCTGACTTATTCTTGCTC-3Ј (sense) and 5Ј-CCTCTGACTTATTCT-TGCTC-3Ј (antisense); p53 exons 8 and 9, 5Ј-CTTGTGCTGTGCCTCCTCTT-3Ј (sense) and 5Ј-CCAATAATAACCTTGGTACC-3Ј (antisense). PCR was repeated at least twice and electrophoresis was performed under two different conditions (acrylamide gel alone and acrylamide gel with 10% glycerol) to confirm the results. If shifted bands were observed by PCR-SSCP analysis, they were cut out from the acrylamide gel to be sequenced.
DNA sequencing
DNA sequences were determined with the ABI PRISM dye terminator cycle sequencing ready reaction kit with AmpliTaq DNA polymerase (Perkin Elmer, Applied Biosystems, Foster City, CA) on the ABI PRISM 310 genetic analyzer (Perkin Elmer, Applied Biosystems).
Statistical analysis
Statistical comparisons between the different groups ( Figure 4A -C) were completed with StatView software (v.4.02; Abacus Concepts, Berkeley, CA) for the Macintosh microcomputer, and significant differences between groups were determined by the Student's paired t-test. A result was only considered statistically significant if P Ͻ 0.05.
Results

Expression of p27 KIP1 during various stages of rat bladder carcinogenesis
Normal rat bladder epithelium constitutively expresses the p27 KIP1 protein ( Figure 1A ). Simple hyperplasia, firstly appearing after carcinogen treatment, stained strongly positive for p27 KIP1 ( Figure 1B) . PN hyperplasia appeared after week 8 and the majority also stained intensely ( Figure 1C , D and F) for p27 KIP1 . Papillomas, which began to appear at week 12, frequently showed diminished staining intensity for p27 KIP1 relative to simple hyperplasia; generally, smaller papillomas stained more intensely than their larger counterparts ( Figure  1G and H). TCCs began to appear at week 18, and the majority of them showed diminished staining. Occasionally no staining was observed ( Figure 1I, J and L) . Two different histological p27 KIP1 in urinary bladder carcinogenesis Fig. 2 . Immunohistochemical assessment of p27 KIP1 in rat urinary bladder lesions induced by BBN and promoted by Na-AsA. p27 KIP1 staining in urinary bladder lesions was scored semi-quantitatively based on the intensity of staining. Only PN hyperplasias were present at week 8. Both PN hyperplasia and papillomas could be observed at week 12. TCCs are present at weeks 18 and 24. The majority of PN hyperplasias had strong or moderate p27 KIP1 staining while the majority of papillomas and TCCs demonstrated moderate or weak staining.
patterns of TCCs could be identified, associated with different patterns of staining; TCCs with abundant stroma generally had negligible staining in the epithelial elements but intense staining of the fibroblasts ( Figure 1I ), while TCCs with rare stroma generally had detectable levels of staining in the epithelial elements ( Figure 1L ). Semi-quantitative evaluation of p27 KIP1 protein expression Sample size requirements for obtaining sufficient amounts of RNA for multiplex RT-PCR analysis did not allow detection of p27 KIP1 mRNA levels in any specific type of preneoplastic lesion. However, using immunohistochemical techniques, we were able to examine p27 KIP1 protein expression in paraffinembedded tissue sections. Overall, the majority of PN hyperplasias demonstrated moderate to strong p27 KIP1 staining while the majority of papillomas and TCCs exhibited only weak to moderate staining (Figure 2) .
Quantitation of p27 KIP1 , p21 WAF1/Cip1 and p53 mRNA expression in tumors
The mRNA levels for cell cycle related elements p27 KIP1 , p21 WAF1/Cip1 and p53 in tumors and normal urothelium were determined by multiplex RT-PCR, a semi-quantitative but highly sensitive method for determining the expression levels of target genes (4). The results shown in Figure 3 are representative of five independent PCR reactions. The great majority of tumors evaluated had reduced p27 KIP1 mRNA levels, as compared with normal bladder mucosa (Figure 3) . A relatively high proportion of tumors analyzed, 42% (5 of 12) of those at week 18 and 47% (7 of 15) at week 24, demonstrated Ͼ50% reduction in their p27 KIP1 mRNA levels (Table II) . A cut-off value of Ͼ50% reduction or incrementation was chosen due to the fact that small individual variation in mRNA levels exists within the control group; however, such variations are always within the cut-off value we selected. Average p27 KIP1 mRNA expression was significantly reduced in tumors at both 18 and 24 weeks ( Figure 4A ).
Reduced mRNA levels of another CDK inhibitor, p21 WAF1/Cip1 were observed in 58% (7 of 12) and 73% (11 of 15) of tumors at weeks 18 and 24, respectively. The respective figures for reduced mRNA levels of p53, an upstream regulator of p21 WAF1/Cip1 , were 50% (6 of 12) and 73% (11 of 15). Average p21 WAF1/Cip1 mRNA expression in tumors was also significantly reduced at both time points ( Figure 4B ). Average p53 mRNA expression was significantly reduced at week 24 but not 18 ( Figure 4C) .
Comparison of the mRNA expression profiles of p27 KIP1 , p21 WAF1/Cip1 and p53 in tumors ( Figure 3 
Absence of p53 mutations and lack of p53 nuclear accumulation in tumor
Twelve tumors taken at week 18 and 15 taken at week 24 were examined for the presence of p53 mutations by PCR-SSCP analysis. None of the tumors we examined harbored mutations within exons 5-9 of the p53 gene (Table II) . Immunohistochemistry for p53 was performed on all TCCs and only two tumors, one from week 18 and another from week 24, showed positive nuclear staining in Ͼ20% of their nuclei.
Topographic distribution of p27 KIP1 relative to PCNA and cyclin D1
To evaluate the topographic distribution of p27 KIP1 relative to PCNA, a marker of cell proliferation in TCCs of human urinary bladder (50, 56) , immunohistochemistry for each of these antigens was performed separately in serial sections. Double staining was also performed on selected specimens to allow precise localization of p27 KIP1 relative to PCNA. A reciprocal expression pattern between p27 KIP1 and PCNA was observed. The majority of lesions stained homogeneously positive for either p27 KIP1 or PCNA ( Figures 1D, E , J and K, and 5B and D). Intratumor heterogeneity was observed in a subset of bladder lesions; regions were positively stained for p27 KIP1 but not for PCNA, or positively stained for PCNA but not for p27 KIP1 ( Figure 5A , C, E, F and G). In well-differentiated TCCs, positive p27 KIP1 nuclear staining was found diffusely throughout the epithelial elements, whereas PCNA nuclear staining was confined to the basal cell layers ( Figure 5H and I). Double immunohistochemistry for cyclin D1 and p27 KIP1 was performed on a selected number of TCCs ( Figure 6 ). A mutually exclusive pattern for cyclin D1 and p27 KIP1 was not observed.
Discussion
Despite clear evidence that p27 KIP1 can function as a negative regulator of cell cycle progression, its precise role in tumorigenesis is still the subject of active investigation. Since p27 KIP1 functions biochemically as a cell cycle inhibitor (21, 24, 25) , a reduction in the protein level of p27 KIP1 is likely to provide a cell with a selective growth advantage. We have presented evidence that reduced expression of p27 KIP1 is a frequent molecular event in two-stage bladder carcinogenesis of rats. Thus, immunohistochemical examination revealed a dramatic decrease of p27 KIP1 protein expression in advanced as compared with early preneoplastic lesions, confirmed by multiplex RT-PCR to be at least partially due to reduction in mRNA levels. Increased degradation of p27 KIP1 in tumors is another possibility, since cell cycle regulation of p27 KIP1 cellular abundance occurs at the post-transcriptional level via proteasome-mediated degradation (57, 58) . The regulatory mechanism of p27 KIP1 expression in rat bladder tumors is the subject of ongoing investigation. Reduced expression of p27 KIP1 protein has not been implicated in human urinary bladder carcinogenesis, but recent studies suggest that patients with breast and colon tumors that display low expression of p27 KIP1 have a poor prognosis (27, 28, 30) . The finding of decreased expression of p27 KIP1 at both the mRNA and protein levels in rat bladder tumors implies a tumor suppressive role for this CDK inhibitor and it is consistent with a normal role of this protein in growth suppression in non-malignant tissues. A recent publication reported that p27 KIP1 knockout mice are predisposed to tumors in multiple tissues when challenged with γ irradiation or the chemical carcinogen N-ethyl-Nnitrosourea (ENU) (59) . Interestingly, the intensity of p27 KIP1 staining was somewhat increased in simple hyperplasia as compared with normal bladder epithelium. A possible explanation is that increased p27 KIP1 in this setting is a physiological response to counteract proliferative signals generated by exposure to carcinogens. In contrast, loss of p27 KIP1 protein expression in the majority of advanced lesions is likely a result of either increased degradation or transcriptional repression of this protein during the course of tumor progression. In a small population of papillomas and TCCs, strong expression of p27 KIP1 protein was seen, possibly indicating the existence of a mechanism by which some growing tumor cells may tolerate this inhibitor of cell cycle progression.
Reduced mRNA expression of p21 WAF1/Cip1 , a CDK inhibitor with structural similarities to p27 KIP1 , was also observed in the present study. This could play a role in rat two-stage bladder carcinogenesis for the following reasons: firstly, p21 WAF1/Cip1 is one of the CDK inhibitors that inhibit kinase activities of preactivated cyclin-CDK complexes (18, 19) and a downstream effector of p53-mediated growth suppression (20, 60) . Secondly, p21 WAF1/Cip1 has been shown to induce a cell cycle arrest by direct binding to PCNA (61) and ectopic overexpression of p21 WAF1/Cip1 in human brain tumor cells results in G 1 -arrested cells (62) . Thirdly, p21 WAF1/Cip1 can function as a tumor suppressor through its ability to control cell cycle progression, and transfection of p21 WAF1/Cip1 into malignant cells has been reported to suppress tumorigenicity in vivo (63) . Finally, p21 WAF1/Cip1 mutations have been reported in TCCs of the human urinary bladder (64, 65) and in human bladder cancer cell lines (66) . KIP1 (brown) in a TCC; intense nuclear staining is apparent in the lower portion while negligible staining is present in the upper portion (ϫ200). (F) Serial section to E stained for PCNA (red); intense nuclear staining is observed predominantly in the upper portion (ϫ200). (G) Double immunohistochemical staining of a serial section to E for p27 KIP1 (black) and PCNA (red) confirms the mutually exclusive staining patterns for these two antigens within the same lesion (ϫ200). (H) TCC with positive nuclear staining for p27 KIP1 (brown) in the epithelical elements; nuclear staining is appreciably stronger in the upper, well-differentiated regions (ϫ100). (I) Serial section to D showing PCNA (red) staining, predominantly in the nuclei of the basal cell layers (ϫ100).
The p53 protein has been described as the cellular gatekeeper for growth and division and a guardian of the genome because of its importance in the mediation of cell cycle arrest and induction of apoptosis in response to DNA damage (67) . Inactivation of p53, primarily due to mutations or deletions, is found in 50-55% of all human cancers (68, 69) . Inactivation of p53 gene appears to have an important role in the tumori-genesis of a subset of urinary bladder carcinomas (70) . Thus, alterations are common in high grade, invasive and nonpapillary tumors of the urinary bladder (71) and are associated with tumor progression (72) . Functional inactivation of the p53 gene in human urinary bladder carcinomas commonly involves an allelic loss of chromosome 17p and mutation of p53 gene on the remaining allele (73) . However, mutations of p53 gene have been reported to be very uncommon in rat bladder tumors induced by the two-stage bladder carcinogenesis protocol; in one experiment in which F344 rats were initiated with FANFT for 6 weeks followed by promotion with 5% NaAsA until week 78, p53 mutations were observed in only two of 17 bladder tumors (74) . In the present study, nuclear accumulation of p53 was detected in only two cases and p53 mutations were not detected in rat bladder tumors induced by the two-stage bladder carcinogenesis protocol of BBN initiation followed by Na-AsA promotion (Table II) ; reduced mRNA levels were noted in tumors (Table II; Figures 3 and 4C) and may indicate a loss of function for this important tumor suppressor gene. It is possible that a loss or reduction of p53 function may be linked to the reduced expression of p21 WAF1/Cip1 mRNA in rat bladder tumors, since p21 WAF1/Cip1 has been shown to be a downstream mediator of p53-mediated growth suppression in vitro (20) . The observation that functional inactivation of p53 gene in rat bladder tumors induced by the two-stage bladder carcinogenesis protocol may result from reduction in mRNA levels rather than mutations is a novel possibility which deserves further investigation. A relationship between loss of p53 function due to reduction in mRNA levels and the acquisition of a malignant phenotype has been established in in vitro experiments. When an immortalized non-tumorigenic rat urothelial cell line strongly expressing wild-type p53 was transfected with an antisense rat p53 RNA, a significant reduction in p53 mRNA expression was observed; the transfected cell lines acquired a malignant phenotype and formed muscle-invasive, high-grade TCCs when injected s.c.
into athymic nude mice (75) . Analysis of the transformed cells revealed a decrease in the expression of p21 WAF1/Cip1 .
Concomitant decrease in p21 WAF1/Cip1 and p53 mRNA levels was observed in 42 and 67% of tumors at weeks 18 and 24, respectively ( Figure 3) . The high concordance rates are consistent with the finding that p21 WAF1/Cip1 is a downstream effector of p53-mediated growth suppression (20) ; a complete concordance between p21 WAF1/Cip1 and p53 mRNA expression, however, should not be expected because p21 WAF1/Cip1 expression can also be regulated by p53-independent pathways (76). An unexpected finding was the observed high concordance rate between p27 KIP1 , p21 WAF1/Cip1 and p53 mRNA levels, reduction of all three being observed in 33 and 40% of the tumors at weeks 18 and 24, respectively. The significance of this is the subject of ongoing investigations.
It has been reported that in normal human tissues, an inverse correlation between expression of p27 KIP1 and cell proliferation is generally observed (34, 77) . In addition, it has been shown that p27 KIP1 gene knock-out mice have increased body weight and multiple organ hyperplasia, suggesting that p27 KIP1 protein inhibits cell proliferation in vivo (78) (79) (80) . Furthermore, p27 KIP1 expression is inversely proportional to the proliferative index in some human malignancies (81) . To a certain extent, a mutually exclusive staining pattern was also observed in our examination of the topographic distribution of p27 KIP1 and PCNA in urinary bladder lesions; lesions with a low proliferative index were mostly positive for p27 KIP1 , whereas tumors characterized by a higher growth fraction had low p27 KIP1 expression. The mutually exclusive pattern of p27 KIP1 and PCNA staining in these lesions indicates that p27 KIP1 plays an important role in negatively controlling cellular proliferation. Overexpression of cyclin D1, a positive regulator of cell cycle progression, has been reported in the two-stage bladder carcinogenesis model (4) . An increase in cyclin D1 and a decrease in either p21 WAF1/Cip1 and/or p27 KIP1 are likely to have similar effects on the cell cycle. Double staining for cyclin D1 and p27 KIP1 was therefore performed to determine whether there is a linkage-negative or positive-between the two types of changes. Among the TCCs we evaluated, a heterogeneous staining pattern was generally observed for both cyclin D1 and p27 KIP1 rather than a mutually exclusive pattern. This result is consistent with our previous observation that there does not exist a simple correlation between cyclin D1 overexpression and cell proliferation in TCCs of the urinary bladder (4, 50) .
The CDK inhibitors p27 KIP1 , p21 WAF1/Cip1 and the tumor suppressor gene p53 are negative regulators of cell cycle progression; inactivation of these cell cycle regulatory elements is likely to result in uncontrolled cell proliferation. The observation that reduced expression of p27 KIP1 , p21 WAF1/Cip1 and p53 is present in rat bladder tumors induced by two-stage bladder carcinogenesis implies that accelerated cell cycle progression is the mechanism behind the carcinogenicity of non-genotoxic chemicals. The reciprocal expression of p27 KIP1 and PCNA in the great majority of lesions further supports this view.
In conclusion, our results suggest that inappropriate downregulaton of p27 KIP1 , p21 WAF1/Cip1 and p53 are associated with malignant tumor development in the rat bladder and may be important in determining the biologic potential of urinary bladder carcinomas. Reduced expression of these cell cycle related elements might account for the increased cell proliferation and the autonomous growth of urinary bladder carcinomas. This study demonstrates that components of the cell cycle machinery have the potential of being targeted and altered during chemical carcinogenesis of the urinary bladder, which partially explains the mechanism of tumor promotion by nongenotoxic carcinogens. Identifying the cellular and molecular targets involved in non-genotoxic chemical carcinogenesis is an important step toward providing a biological basis for the phenotypic changes observed during rat bladder carcinogenesis. It is of interest that the mechanisms involved in downregulation of these important cell cycle related elements now be determined, because such findings could potentially lead to novel therapeutic strategies for urinary bladder carcinomas.
